Biological E. on Monday said the Phase I/II clinical trial of its COVID-19 subunit vaccine candidate has been initiated in the country.
The Hyderabad-based vaccines and pharmaceutical firm made this announcement with US-based biopharmaceutical firm Dynavax Technologies Corporation and Baylor College of Medicine, Houston. The launch of the trial follows approval from the Drugs Controller General of India (DGCI).
A release from Biological E. said the vaccine candidate includes an antigen in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialisation team, along with Dynavax’s advanced adjuvant CpG 1018.
BE's Phase I/II clinical trial will evaluate the safety and immunogenicity of the vaccine candidate in about 360 healthy people in the 18 to 65 age group. The vaccination schedule consists of two doses for each participant, administered via intramuscular injection 28 days apart. The results of this clinical trial are expected to be available by February.
“We are very happy indeed to transition our potential vaccine candidate to clinical trials and offer one more potential option for the prophylaxis of Covid-19,” said Mahima Datla, Managing Director of Biological E.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
Please Email the Editor